The Trichotillomania Coverage Report

Trichotillomania is often summarized as recurrent hair pulling, but the statistics show that a useful coverage picture has to be much wider. Coverage therefore means more than counting cases; it means tracking how the condition becomes visible across symptoms, daily burden and healthcare systems.

The available datasets also show why one headline percentage cannot stand for every setting. A large U.S. adult survey identified current trichotillomania in 1.7% of 10,169 respondents, while a Swedish national-register study found 1,234 specialist-diagnosed individuals after exclusions in a source population of almost 13 million residents. These are not competing estimates. Their difference illustrates how study design, recruitment, diagnosis and observation window shape the numbers that appear in a report.

The same principle applies to clinical detail. An online DSM-5 cohort adds information on pulling locations, onset and duration. An international clinical sample adds symptom severity and comorbidity clusters. Read together, these statistics support a layered model of coverage: detect the condition, identify when it began, describe how pulling is expressed, measure burden, map associated conditions and then examine how often people receive professional care or treatment.

Executive Trichotillomania Coverage Benchmarks

The numbers that define the coverage picture

The strongest executive benchmark is the 1.7% current-prevalence estimate in the U.S. adult sample. Out of 10,169 respondents aged 18 to 69, 175 met the study criteria for current trichotillomania. Overall prevalence was nearly identical when men and women were considered as broad groups: 1.8% among men and 1.7% among women. That overall similarity should not be mistaken for identical age patterns, because the age-specific strata differ more sharply and show a clear drop in the oldest groups.

Healthcare recognition forms a second benchmark. Of the 175 adults identified with current trichotillomania, 110 reported having been diagnosed by a healthcare professional, equal to 62.9%. When the survey estimate is restricted to those cases with professional attention, the conservative prevalence falls to 0.98%. This gap is one of the most important coverage signals in the report: a condition can be present in a community sample without appearing in professional records or without being remembered as a formal diagnosis.

Onset and burden add depth to that prevalence picture. Mean age at onset in the U.S. current-TTM sample was 17.7 years, with observed onset ranging from age 1 to age 61. Participants reported pulling from an average of 2.5 bodily areas and a median of 2. Mean hair-loss noticeability was 4.3 on a 1-to-7 scale, while mean distress was higher at 5.1. These numbers show why prevalence should be connected to experience: a person can be counted as a current case while carrying very different combinations of visibility, distress and multi-site pulling.

The wider evidence set shows that clinical complexity is common. In the same U.S. current-TTM sample, 79% had at least one mental-health comorbidity. In the Swedish specialist cohort, 68% had any psychiatric disorder before or at first TTM diagnosis and 79% had one at any time during the study period. The international clinical cohort reported 55.3% lifetime major depressive disorder.

 

 

Why Trichotillomania Requires a System-Based Coverage Benchmark

A system-based benchmark is necessary because each data source sees a different layer of the condition. Clinical cohorts offer deeper symptom measurement but are shaped by referral and treatment-seeking. Online recruitment can capture long-standing symptoms that may be underrepresented in face-to-face clinics, yet it introduces its own selection patterns.

The distinction becomes concrete when the U.S. and Swedish numbers are placed side by side. The U.S. adult survey identified 1.7% current prevalence, whereas the Swedish register cohort represented roughly 0.01% of the source population as recorded specialist-diagnosed TTM. Treating those values as interchangeable would confuse symptom detection with diagnosed service use.

Coverage should therefore proceed as a sequence. First identify symptoms and prevalence. Then establish age at onset and duration. Next describe pulling sites, visible hair loss and distress. Add psychiatric comorbidity and related body-focused repetitive behaviors. Finally, examine diagnosis, treatment exposure and longitudinal outcomes. A report that preserves these layers can explain where the evidence is strong and where it remains incomplete without forcing every statistic into one synthetic rate.

 

Trichotillomania Prevalence in Adults

What a large U.S. adult sample reveals

The large U.S. adult study provides the clearest population-scale prevalence signal in the dataset. Among 10,169 adults aged 18 to 69, 175 met the criteria for current trichotillomania, producing a prevalence estimate of 1.7%. The value is large enough to show that clinically meaningful hair pulling is not confined to small specialty clinics, yet it should remain attached to the survey design rather than be presented as a universal figure for every country, age group or diagnostic method.

The sex-specific totals were close: 1.8% among 5,045 men and 1.7% among 5,087 women. That similarity does not conflict with the strongly female-skewed composition of many clinical cohorts. Treatment-seeking, referral patterns and study recruitment can produce very different sex distributions even when a population survey shows comparable overall prevalence.

The age-stratified estimates are more revealing. Men aged 18 to 29 had 2.5% prevalence and men aged 30 to 49 had 2.6%, compared with only 0.5% at ages 50 to 69. Women showed 2.6% at ages 18 to 29, 1.8% at 30 to 49 and 0.9% at 50 to 69. These strata make age an essential part of any prevalence statement, because the overall average hides substantial variation across the adult life course.

Figure 1. Age-specific prevalence varies more visibly than the near-equal overall male and female estimates, showing why aggregate gender figures should be interpreted alongside age strata.

 

Age at Onset and the Early Clinical Window

Age at onset is one of the most consistent signals across otherwise different study designs. In the U.S. current-TTM sample, mean age at onset was 17.7 years. Male participants reported a later mean onset of 19.0 years, while the female mean was 14.8 years; the reported comparison had a p-value of 0.02. The observed onset range was extremely wide, from age 1 to age 61, reminding readers that a typical age does not define every individual trajectory.

Other cohorts shift the mean younger. The online DSM-5 cohort of 259 adults reported a mean onset age of 12.5 years with a standard deviation of 6.9 years. The international clinical cohort of 304 adults reported mean onset at 13.4 years with a standard deviation of 5.8 years and a range from age 1 to age 45. These values cluster around childhood and adolescence more clearly than the U.S. adult survey mean, but the studies differ enough that averaging them would erase useful context.

The onset numbers become especially important when compared with the Swedish register. In that specialist-diagnosed cohort, median age at first recorded diagnosis was 24.6 years and mean age was 27.6 years. Those values are not direct measures of delay for the same individuals because the onset figures come from different studies, yet they illustrate a recurring coverage problem: research cohorts often describe pulling beginning well before the ages at which many people appear in specialist records. Early recognition therefore deserves its own benchmark rather than being inferred from age at diagnosis.

Figure 2. Reported mean onset ages differ across study cohorts, with several clinical and online samples centering in early adolescence while the U.S. adult survey shows a later average.

 

Hair-Pulling Phenomenology

Frequency, episode size and visible consequences

The Italian phenomenology study shows why coverage must describe the behavior itself, not simply whether a diagnosis is present. The combined sample included 122 adults with TTM. Bald spots caused by pulling were reported by 94 people, or 78.3%. Among those with bald spots, 32.6% described an area smaller than 1 centimeter, 44.2% reported 1 to 5 centimeters, 17.9% reported 6 to 10 centimeters and 5.3% reported an area larger than 10 centimeters. The largest share therefore fell in the 1-to-5-centimeter band, while a smaller group reported substantially more extensive visible loss.

Episode size also varied widely. Only 8.2% reported pulling one hair per episode. A further 26.2% reported 2 to 5 hairs, 23.0% reported 6 to 10 hairs, 29.5% reported 11 to 30 hairs and 13.1% reported more than 30 hairs. Frequency, number of hairs and visible consequences should therefore remain separate measurements when a study or service wants to understand burden.

Hand preference adds another layer of detail that a diagnosis code cannot capture. In the Italian sample, 59.5% reported pulling with the dominant hand and 37.7% with the non-dominant hand. These patterns reinforce the value of recording how pulling occurs, not only where it occurs or whether visible hair loss is present.

 

 

Where Hair Pulling Occurs

Anatomical location is one of the most visually interpretable parts of the dataset. In the combined Italian TTM sample, scalp pulling was reported by 80.3%, making it the dominant site. The next most common areas were the pubic region at 35.2% and eyebrows at 34.4%. Eyelashes were reported by 21.3%, legs by 17.2% and the armpit by 10.7%. Lower-frequency sites included the face at 9.0%, mustache and beard at 5.7% each, arms at 5.7%, stomach at 3.3% and chest at 2.5%.

A separate online DSM-5 cohort shows both consistency and variation. Scalp pulling was again dominant at 79.5%, very close to the Italian combined figure. Eyebrow pulling was higher at 54.8%, eyelid pulling at 49.0%, pubic-region pulling at 47.1% and leg pulling at 22.4%. These values should not be averaged with the Italian estimates, because recruitment and measurement differ, but they reinforce the core point that trichotillomania frequently involves more than one anatomical area.

The U.S. current-TTM sample supports the same multi-site interpretation from another angle: participants pulled from an average of 2.5 bodily areas and a median of 2. A coverage framework that asks only about the scalp risks underdescribing the behavior and its maintenance patterns.

Figure 3. Scalp pulling dominates the selected Italian site profile, while eyebrows, eyelashes, pubic-region hair and other body areas show that trichotillomania frequently extends beyond a single location.

 

Online Versus Face-to-Face Phenomenology

The Italian study also separated online and face-to-face groups, creating a useful reminder that recruitment changes the measured picture. Scalp pulling was reported by 82.7% of the online group and 70.8% of the face-to-face group. Eyebrow pulling was similar at 34.7% and 33.3%, while eyelash pulling was 23.5% online versus 12.5% face to face. These differences illustrate how some sites remain stable across recruitment methods while others shift more noticeably.

The largest contrast involved the pubic region: 41.8% in the online group compared with 8.3% in the face-to-face group. The reported group comparison for pubic-region pulling had a p-value of 0.04. It should therefore be used as evidence that setting matters, not as proof that online participants are representative of a different underlying population.

For coverage design, the practical lesson is straightforward. Sensitive questions may produce different responses depending on how they are asked and where participants are recruited. Studies and services should preserve recruitment mode in their data models and avoid merging online and clinic groups without noting the context. That preserves interpretability when site-specific rates diverge.

 

Distress, Noticeability and Clinical Burden

The U.S. current-TTM sample provides a compact set of burden measures on the same 1-to-7 scale. Mean hair-loss noticeability was 4.3 with a standard deviation of 1.9, while mean distress was 5.1 with a standard deviation of 1.8. Mean severity was 4.4 at first diagnosis, 5.2 at the worst point and 4.1 currently. The pattern suggests improvement from the remembered worst point while meaningful distress remains.

Sex differences appeared more clearly in the extreme response categories than in overall prevalence. Among women with current TTM, 42% endorsed the most severe distress score of 7, compared with 18% of men. Major life impact at the maximum score was reported by 32% of women and 12% of men. These are subgroup findings within one survey and should not be generalized beyond that context, but they show why broad prevalence parity can coexist with different reported burden profiles.

The distinction between visibility and distress is especially important. A mean noticeability score of 4.3 and mean distress of 5.1 indicate that the emotional burden can exceed how obvious the hair loss is perceived to be. Clinical assessment should therefore avoid using visible loss as a proxy for severity. People may experience substantial urges, shame, interference or effort to conceal pulling even when an observer sees relatively limited hair change.

 

 

Reward, “Wanting,” and the Pulling Experience

The online reward-processing cohort adds a different kind of coverage: the internal experience around pulling. It included 259 adults meeting DSM-5 TTM criteria, of whom 250 were women and 9 were men. The mean age was 32.0 years with a standard deviation of 12.2 years. Mean onset was 12.5 years and mean duration was 19.1 years, showing that this was largely a long-standing adult sample rather than a group describing only recent symptoms.

Its pulling-site profile was broad, with 79.5% reporting scalp pulling, 54.8% eyebrows, 49.0% eyelid hair, 47.1% pubic-region hair and 22.4% leg hair. That distinction matters because two people with similar pulling frequency may differ in whether the strongest process is anticipatory urge, sensory reward, relief or another component of the episode.

For a statistics report, this evidence prevents phenomenology from being reduced to counts and anatomical sites. It also helps explain why pulling frequency alone may not track distress, reinforcement or treatment need.

 

Psychiatric Comorbidity

Comorbidity is one of the clearest high-burden signals across the evidence set. In the U.S. current-TTM sample, 79% had at least one mental-health comorbidity. Any anxiety disorder was reported by 53%, depression by 45%, ADHD by 29%, PTSD by 29% and OCD by 29%. Current skin-picking disorder affected 24%, equal to 42 of the 175 current TTM cases. These overlapping conditions mean that hair pulling frequently sits inside a broader clinical picture rather than appearing as a completely isolated symptom pattern.

The Swedish national-register cohort shows how the comorbidity picture expands over time. Before or at the first TTM diagnosis, 68% had any psychiatric disorder; across the full study period the figure reached 79%. Anxiety-related disorders rose from 51% before or at diagnosis to 65% at any time. Depressive disorders rose from 36% to 48%, neurodevelopmental disorders from 24% to 39%, ADHD from 19% to 34%, OCD from 18% to 24%, and severe stress or adjustment disorders from 16% to 27%.

Other register categories add additional complexity. Pervasive developmental disorders increased from 9% before or at diagnosis to 16% at any time. Bipolar disorders rose from 4% to 8%. Eating disorders increased from 8% to 10%, and emotionally unstable personality disorder from 7% to 10%. Tourette or chronic tic disorders remained at 3% in both observation windows. These numbers should be interpreted as diagnosed comorbidity in specialist records, not as direct prevalence estimates for all people with TTM.

The coverage implication is clear. A cross-sectional assessment at first diagnosis will miss conditions recognized later, whereas longitudinal records reveal how psychiatric complexity accumulates across the care timeline.

Figure 4. Several psychiatric conditions become more prevalent when the observation window extends beyond the point of trichotillomania diagnosis.

 

Clinical Comorbidity Profiles and Clusters

The international clinical cohort of 304 adults provides a more detailed view of how comorbidity can organize into recognizable profiles. Women represented 94.4% of the sample, with 287 female participants. Mean age was 32.8 years and mean age of pulling onset was 13.4 years. Mean MGH-HPS severity was 14.8 with a standard deviation of 4.8, while the mean BDI-I score was 10.85 with a standard deviation of 8.43.

Lifetime major depressive disorder was present in 168 participants, equal to 55.3%. For the subset with onset data, mean age at MDD onset was 22.2 years. The correlation between MGH-HPS and BDI scores was 0.25 with a reported p-value of 0.06, indicating that hair-pulling severity and depressive symptom burden were related only modestly in this analysis. That separation reinforces the value of measuring TTM and depression independently rather than assuming one scale can stand in for the other.

Cluster analysis divided the sample into three broad profiles. A simple TTM cluster contained 63 people, or 20.7%. A depressive TTM cluster contained 49 people, or 16.12%. The largest was a complex TTM cluster with 192 people, equal to 63.16%. Within the complex cluster, lifetime major depression was present in 62%, OCD in 36% and skin-picking in 24%. The size of this complex cluster shows why a single average patient profile can be misleading in specialty-care datasets.

From a coverage perspective, cluster evidence supports keeping sub-scores visible. Overall severity can be reported while still distinguishing depressive, obsessive-compulsive-spectrum and other comorbidity patterns that may shape care needs.

 

Professional Diagnosis and Healthcare Recognition

Professional recognition is one of the clearest dividing lines between population coverage and clinical coverage. In the U.S. survey, 110 of the 175 adults meeting current TTM criteria reported that a healthcare professional had diagnosed the condition. That equals 62.9%, leaving a substantial share of current cases without self-reported professional diagnosis. The conservative prevalence based on the 110 professionally diagnosed cases was 0.98% of the 10,169-person survey sample.

The professionally diagnosed subgroup also differed demographically from many clinical samples. Men represented 55.5% of professionally diagnosed current cases, equal to 61 of 110. Different pathways into studies and care can generate sharply different sex distributions.

For coverage systems, the essential metric is the conversion from symptoms to professional recognition. Without that distinction, a high diagnosed-case count can appear to indicate strong coverage even when a substantial share of the underlying community burden remains outside formal care.

Figure 5. In the U.S. current-TTM sample, 110 of 175 qualifying cases reported professional diagnosis, equivalent to 62.9%.

 

Family History and Familiality

The familiality study compared 173 probands across three groups: 69 with TTM only, 34 with excoriation disorder only and 70 with both TTM and excoriation disorder. First-degree family history of TTM was reported by 25% of the TTM-only group, 6% of the ED-only group and 21% of the combined TTM+ED group. The TTM-only versus ED-only comparison for TTM family history had a reported p-value of 0.03.

The reverse pattern appeared for excoriation-disorder family history. ED history was reported by 13% of TTM-only probands, 41% of ED-only probands and 39% of the combined group. The TTM-only versus ED-only comparison had a reported p-value of 0.002. These results support disorder-specific familial clustering while also showing substantial overlap in the group with both body-focused repetitive behaviors.

The family-history table extends beyond TTM and ED. Anxiety family history ranged from 48% in TTM-only probands to 59% in both the ED-only and combined groups. Depression family history was 41%, 47% and 49% respectively. ADHD family history ranged from 23% to 31%, while OCD family history was tightly grouped at 17% to 18%. These percentages do not establish genetic causation, but they show why a family-history section should include related psychiatric and body-focused repetitive behavior categories rather than asking about hair pulling alone.

For practical coverage, the key is to preserve the proband group and the family-history condition as separate fields. That allows a report to detect disorder-specific patterns without flattening every first-degree history into one undifferentiated psychiatric-family-risk score.

Figure 6. First-degree family history differs by proband group, with TTM history highest in the TTM-only group and ED history highest in ED-containing groups.

 

Swedish National-Register Coverage

The Swedish register study provides the largest healthcare-system frame in the dataset. Its source population contained 12,987,753 residents observed from 1997 to 2020. A total of 1,290 individuals had a recorded TTM diagnosis before exclusions. Fifty-six people, or 4.34% of those diagnosed, were excluded because of intellectual disability, leaving a final analytic cohort of 1,234 specialist-diagnosed individuals.

Age at first diagnosis centered in young adulthood but varied widely. The median was 24.6 years, with an interquartile range of 16.35 to 35.3 years; the mean was 27.6 years with a standard deviation of 15.79 years. Compared with the earlier mean onset reported in several other cohorts, these figures highlight the importance of distinguishing symptom onset from entry into recorded specialist care.

The register also provides sociodemographic context. Eighty-four percent were born in Sweden and 16% abroad. Eighty-two percent were recorded as single, 11% married or cohabiting and 7% had missing marital status. Education was elementary for 36%, secondary for 28%, higher for 25% and missing for 10%. Income was in the lowest quintile for 17%, the middle 60% for 53%, the top quintile for 22% and missing for 7%.

Birth-cohort distribution shows that recorded diagnosis spans generations: 15% were born in 1969 or earlier, 13% in the 1970s, 22% in the 1980s, 28% in the 1990s, 20% from 2000 to 2009 and 2% in 2010 or later. The spread underscores that register coverage reflects a broad age range rather than a narrowly defined youth cohort.

 

 

Medication and Treatment Exposure

Medication dispensing around the first TTM diagnosis adds another healthcare-use layer to the Swedish register. The medication sub-cohort included 1,228 people who were alive and resident during the relevant window, representing 99.5% of the main cohort. The observation window covered 12 months before through 12 months after first diagnosis, allowing medication exposure to be interpreted around the point at which TTM entered specialist records.

Any psychotropic medication was dispensed to 888 people, equal to 72% of the medication sub-cohort. Antidepressants were dispensed to 715 people, or 58%. Hypnotics or sedatives were dispensed to 447 people, or 36%, and anxiolytics to 385 people, or 31%. The high exposure rates are consistent with the heavy psychiatric comorbidity in the same register population.

These dispensing statistics do not establish that the medications were prescribed specifically for hair pulling. A stronger treatment dashboard would record drug class, timing relative to TTM diagnosis and co-occurring diagnoses so that psychotropic exposure is not mistaken for TTM-specific treatment.

Figure 7. Psychotropic medication exposure was common around first TTM diagnosis in the Swedish medication sub-cohort, with antidepressants the largest named class.

 

Pediatric Treatment Evidence

What the controlled pediatric trial shows

Controlled pediatric evidence in the dataset comes from a 12-week randomized, double-blind trial of N-acetylcysteine. The study enrolled 39 children and adolescents aged 8 to 17, with 20 assigned to NAC and 19 to placebo. The NAC dose was increased over four weeks to a maximum of 2,400 mg per day. Because the trial compared two groups prospectively, its outcome statistics should be read differently from the descriptive treatment exposure in registers.

Clinician-rated response was 25% in the NAC group and 21% in the placebo group. On the MGH-HPS, the NAC mean decreased from 13.15 at baseline to 10.70 at endpoint. The placebo mean decreased from 16.58 to 13.53. The reported effect of time was significant, with F=9.31 and p=0.002, but the treatment effect had F=0.36 and p=0.55, and the interaction p-value was 1.00. The key interpretation is that both groups improved while the data did not show a superior NAC effect on the primary severity measure.

Other outcome measures show a similar need for controlled interpretation. The TSC Child mean moved from 2.35 to 2.00 in the NAC group and from 2.52 to 2.08 in placebo. The time effect had p=0.006, while the treatment effect p-value was 0.52 and interaction p=0.76. Parent-rated TSC means also improved in both groups, from 2.20 to 1.83 for NAC and from 2.32 to 1.88 for placebo, with treatment p=0.66.

For coverage reporting, the trial is a useful guardrail against treating within-group improvement as evidence of efficacy. Baseline-to-endpoint change should be interpreted alongside the control group, responder rates and the reported treatment effect.

Figure 8. Mean MGH-HPS scores declined in both pediatric trial groups; responder rates were 25% with NAC and 21% with placebo.

 

Geographic and Study-Setting Coverage

The evidence base is geographically and methodologically uneven, and the report is stronger when that unevenness remains visible. Sweden contributes national specialist-register evidence on sociodemographics, comorbidity and medication exposure; the United States contributes adult prevalence, professional recognition, familiality and pediatric trial data; Italy contributes detailed phenomenology; and international or online cohorts add severity, reward processing and pulling-site detail.

Each setting is therefore best suited to a different question. The U.S. survey is strongest for current adult prevalence and recognition gaps. The Italian sample is strongest for the physical pattern of pulling. The Swedish register is strongest for specialist-care trajectories and psychiatric context, while clinical and online cohorts provide deeper symptom characterization.

These figures should not be forced into a single international ranking. Denominators, recruitment methods and outcomes differ too substantially. Geographic labels are most useful when they identify the context in which a statistic was measured and the question that statistic can reasonably answer.

 

 

Building the Trichotillomania Coverage Benchmark Index

The Trichotillomania Coverage Benchmark Index converts the report into eight weighted coverage pillars. Symptom identification and prevalence receive 16%, reflecting the need to establish who is captured at the population level. Psychiatric comorbidity receives 15%, while age at onset and duration and pulling-site and phenomenology coverage each receive 14%.

Distress and functional burden receive 13%, separating the presence of pulling from its impact on daily life. Healthcare recognition receives 11%, reflecting the gap between current cases and professional diagnosis. Treatment and longitudinal follow-up receive 9%, while family and related-condition history receive 8%.

Scores from 0 to 39 indicate limited coverage, 40 to 59 basic coverage, 60 to 74 developing clinical coverage, 75 to 89 comprehensive coverage and 90 to 100 advanced longitudinal coverage. Sub-scores should remain visible so that strong performance in one domain cannot conceal gaps in another.

Figure 9. The index gives greatest combined weight to symptom detection, psychiatric comorbidity, onset and phenomenology because complete coverage requires both population and clinical dimensions.

 

Major Trichotillomania Coverage Challenges

The first challenge is detection. The U.S. survey identified 175 current cases, but only 110 reported professional diagnosis. Community surveys can reveal symptoms outside formal care, whereas clinical records capture only people who reach and are recorded by healthcare systems.

The second challenge is measurement heterogeneity. Study populations, recruitment methods, instruments and observation windows differ. Strong statistical storytelling keeps those methods attached to the numbers instead of forcing unlike estimates into a single average.

The third challenge is clinical complexity. Psychiatric comorbidity, multi-site pulling, visible hair loss and treatment exposure do not always emerge at the same time. Coverage is strongest when repeated measurement connects those dimensions rather than treating them as isolated snapshots.

 

90-Day Trichotillomania Coverage Framework

Days 1 to 30 should establish the identification baseline. Record onset age, pulling frequency, episode pattern, affected sites, visible hair loss, severity, distress and functional impact. Distress and life impact should be scored directly rather than inferred from photographs or the visibility of hair loss.

Days 31 to 60 should add clinical context. Record relevant psychiatric comorbidity, family history of TTM and excoriation disorder, healthcare use, prior treatment and medication exposure. This stage turns a symptom profile into a broader care profile.

Days 61 to 90 should focus on change. Reassess severity, distress, affected sites, treatment adherence and functional impact, and document any relapse or return of symptoms. A 90-day framework does not declare cure or failure; it creates a consistent early longitudinal record.

 

Metrics Researchers and Clinical Services Should Track

Symptom metrics should include pulling frequency, episode size, urge intensity where available, affected locations, number of bodily areas and a validated severity score. The Italian and U.S. datasets show why several dimensions are needed to describe the same diagnosis.

Physical-impact metrics should include hair-loss noticeability, bald-spot location and size, concealment strategies when measured, and change over time. Comorbidity should be recorded by diagnosis and timing so that conditions present before, at and after TTM diagnosis remain distinguishable.

Care metrics should include professional diagnosis, clinician type, treatment initiation, behavioral treatment, medication classes, treatment completion and follow-up. Outcome reporting should retain both absolute scores and change over time so improvement is not detached from baseline severity.

 

How Coverage Changes by Care Setting

Primary care can be an important recognition point when patients disclose pulling, distress or related anxiety and depression. Dermatology can become the entry point when hair loss is the presenting concern. Coordination matters when the physical sign is more obvious than the underlying behavior.

Mental-health services are positioned to assess diagnostic criteria, urges, impairment and psychiatric comorbidity in greater depth. The high comorbidity figures in both U.S. and Swedish data make this especially important for care planning and follow-up.

Research registries and national health systems provide the strongest longitudinal coverage, while pediatric services are critical when symptoms begin before adulthood. No single setting captures the entire condition, so comprehensive coverage depends on linking these different points of contact.

 

The Trichotillomania Coverage Report FAQ

What percentage of adults have trichotillomania?

 In the large U.S. sample of 10,169 adults aged 18 to 69, 1.7% met the study criteria for current trichotillomania, equal to 175 people. The estimate belongs to that survey design and should not be treated as a universal rate for every population or healthcare system.

Does trichotillomania affect men and women differently?

Overall U.S. prevalence was very similar at 1.8% for men and 1.7% for women, but age-specific patterns differed and many clinical or online cohorts were strongly female-predominant. Sex distribution therefore changes with population, age and recruitment setting.

At what age does hair pulling usually begin?

 Several cohorts place mean onset in childhood or adolescence. The online DSM-5 cohort reported 12.5 years, the international clinical cohort 13.4 years and the U.S. current-TTM sample 17.7 years. Onset ranges were broad, so these means describe study groups rather than a fixed rule.

Is scalp hair the most common pulling site?

Yes in the detailed site datasets used here. The combined Italian sample reported 80.3% scalp pulling and the online DSM-5 cohort 79.5%. Eyebrows, eyelashes or eyelid hair, pubic-region hair and legs were also common enough to make multi-site assessment important.

Can trichotillomania involve several body areas?

The U.S. current-TTM sample reported an average of 2.5 bodily areas and a median of 2. The site distributions in Italy and the online cohort also show substantial pulling outside the scalp.

How often is trichotillomania professionally diagnosed?

 In the U.S. survey, 110 of 175 current cases reported a professional diagnosis, equal to 62.9%. That is a study-specific indicator of healthcare recognition rather than a global treatment-seeking rate.

Are psychiatric comorbidities common?

Yes in the selected studies. Seventy-nine percent of the U.S. current-TTM sample had at least one mental-health comorbidity. In the Swedish specialist cohort, 68% had any psychiatric disorder before or at first diagnosis and 79% at any time during the study period.

Why do survey and register statistics look so different?

 A survey can identify current symptoms in the community, including people outside treatment. A register counts people whose diagnosis enters a healthcare system. The two approaches measure different layers of coverage and should not be expected to produce matching rates.

Final Takeaway

The statistical picture begins with prevalence but does not end there. In a U.S. sample of 10,169 adults, 175 met current TTM criteria, producing a 1.7% prevalence estimate. Only 110 of those current cases reported professional diagnosis, showing why community burden and healthcare recognition must remain separate measures.

Onset and phenomenology show what those cases look like over time. Mean onset was 12.5 years in the online DSM-5 cohort, 13.4 years in the international clinical cohort and 17.7 years in the U.S. adult sample. Scalp pulling approached 80% in two detailed site datasets, while multi-site involvement and visible hair loss were also common.

Clinical complexity completes the coverage picture. The U.S. current-TTM sample reported 79% with at least one mental-health comorbidity; the Swedish specialist cohort showed 68% with any psychiatric disorder before or at diagnosis and 79% at any time. Comprehensive coverage therefore means tracking prevalence, onset, pulling patterns, burden, comorbidity, family context, professional recognition and change over time within the same evidence framework.